PartnershipUpdated on 8 September 2025
EXORPHIA is seeking partners for EV therapeutics & delivery (EXP01, EXP03) and an IVF adjunct.
About
EXORPHIA is pioneering next-generation therapeutics based on extracellular vesicles (EVs) to deliver innovative medicines that surpass the limits of existing treatments.
Through proprietary technologies, we have established high-activity EVs (Prime-EV), engineered EVs that can be flexibly loaded with antigens or drugs (Engineered EV), and an Advanced CMC platform that ensures reproducibility—all underpinned by a robust patent portfolio.
Our lead pipeline comprises three pillars:
(1) an IVF adjunct for infertility treatment (commercial launch in Japan planned for 2027–2028)
(2) an anti-inflammatory/anti-fibrotic therapy targeting ARDS, IPF, and atopic dermatitis (EXP01; aiming for a disease-modifying profile)
(3) an intranasal EV vaccine (EXP03; applicable from infectious-disease prevention to autoimmunity and oncology).
Through these programs, we will deliver safe, minimally invasive, and highly effective new treatments to clinical practice, and ultimately establish EVs as a versatile DDS platform to set a new standard for refractory diseases and preventive medicine.
We would be pleased to discuss our programs in more detail at the event.
Organisation
Similar opportunities
Project cooperation
Therapeutic for lung injury (ARDS, IPF) using MSC-derived Extracellular Vesicles(
- Planning
- Research
- Technical
- Financing
Project cooperation
- Planning
- Research
- Technical
- Financing
Project cooperation
Atopic Dermatitis Therapy Using MSC-Derived Extracellular Vesicles
- Planning
- Research
- Technical
- Financing